
Sangamo Therapeutics (SGMO) shares slumped over -30% lower due to a failed Phase 1/2 study. The company reported its SB-318 genome editing product did not appear to show any clinical benefits. The company does have an extensive pipeline of treatments in clinical trials, as well as partnerships with major companies such as Pfizer. However, this was not enough for traders to keep the price stable near yesterday’s close. Here’s a recap.